Maywufa Company Ltd. (1731.TW)
TWD 21.8
(0.0%)
TWD 21.8
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.3 Billion TWD | 4.47% |
| 2022 | 1.24 Billion TWD | -3.42% |
| 2021 | 1.28 Billion TWD | 21.02% |
| 2020 | 1.06 Billion TWD | -3.23% |
| 2019 | 1.1 Billion TWD | -2.01% |
| 2018 | 1.12 Billion TWD | -28.68% |
| 2017 | 1.57 Billion TWD | 9.15% |
| 2016 | 1.44 Billion TWD | 5.4% |
| 2015 | 1.36 Billion TWD | 11.06% |
| 2014 | 1.23 Billion TWD | -18.48% |
| 2013 | 1.51 Billion TWD | -29.56% |
| 2012 | 2.14 Billion TWD | -4.46% |
| 2011 | 2.24 Billion TWD | -25.32% |
| 2010 | 3 Billion TWD | 5.26% |
| 2009 | 2.85 Billion TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 350.27 Million TWD | -14.09% |
| 2024 Q1 | 407.7 Million TWD | 21.05% |
| 2023 Q2 | 315.3 Million TWD | -8.6% |
| 2023 Q1 | 344.97 Million TWD | 11.77% |
| 2023 Q4 | 336.79 Million TWD | 10.92% |
| 2023 Q3 | 303.64 Million TWD | -3.7% |
| 2023 FY | 1.3 Billion TWD | 4.47% |
| 2022 Q1 | 338.39 Million TWD | 2.69% |
| 2022 Q3 | 307.6 Million TWD | 5.9% |
| 2022 FY | 1.24 Billion TWD | -3.42% |
| 2022 Q4 | 308.64 Million TWD | 0.34% |
| 2022 Q2 | 290.45 Million TWD | -14.17% |
| 2021 FY | 1.28 Billion TWD | 21.02% |
| 2021 Q1 | 308.63 Million TWD | 14.43% |
| 2021 Q2 | 310.73 Million TWD | 0.68% |
| 2021 Q3 | 340.31 Million TWD | 9.52% |
| 2021 Q4 | 329.52 Million TWD | -3.17% |
| 2020 FY | 1.06 Billion TWD | -3.23% |
| 2020 Q2 | 238.98 Million TWD | -9.84% |
| 2020 Q1 | 265.05 Million TWD | 7.3% |
| 2020 Q3 | 291.57 Million TWD | 22.01% |
| 2020 Q4 | 269.71 Million TWD | -7.5% |
| 2019 Q1 | 315.47 Million TWD | 13.81% |
| 2019 Q3 | 258.79 Million TWD | -7.43% |
| 2019 Q4 | 247.02 Million TWD | -4.55% |
| 2019 FY | 1.1 Billion TWD | -2.01% |
| 2019 Q2 | 279.56 Million TWD | -11.38% |
| 2018 FY | 1.12 Billion TWD | -28.68% |
| 2018 Q2 | 272.66 Million TWD | -10.1% |
| 2018 Q1 | 303.31 Million TWD | -21.28% |
| 2018 Q4 | 277.19 Million TWD | 2.58% |
| 2018 Q3 | 270.22 Million TWD | -0.9% |
| 2017 Q2 | 396.39 Million TWD | 4.98% |
| 2017 Q3 | 415.8 Million TWD | 4.9% |
| 2017 FY | 1.57 Billion TWD | 9.15% |
| 2017 Q1 | 377.58 Million TWD | -0.98% |
| 2017 Q4 | 385.29 Million TWD | -7.34% |
| 2016 Q3 | 369.16 Million TWD | 7.56% |
| 2016 FY | 1.44 Billion TWD | 5.4% |
| 2016 Q4 | 381.32 Million TWD | 3.29% |
| 2016 Q2 | 343.22 Million TWD | -1.75% |
| 2016 Q1 | 349.34 Million TWD | 0.64% |
| 2015 Q2 | 341.47 Million TWD | -1.75% |
| 2015 Q1 | 347.56 Million TWD | 8.38% |
| 2015 FY | 1.36 Billion TWD | 11.06% |
| 2015 Q4 | 347.12 Million TWD | 4.23% |
| 2015 Q3 | 333.03 Million TWD | -2.47% |
| 2014 Q3 | 317.59 Million TWD | 6.37% |
| 2014 Q2 | 298.57 Million TWD | 0.87% |
| 2014 FY | 1.23 Billion TWD | -18.48% |
| 2014 Q1 | 296.01 Million TWD | 2.41% |
| 2014 Q4 | 320.68 Million TWD | 0.97% |
| 2013 Q4 | 289.04 Million TWD | 6.12% |
| 2013 Q2 | 377.69 Million TWD | -34.11% |
| 2013 Q3 | 272.36 Million TWD | -27.89% |
| 2013 FY | 1.51 Billion TWD | -29.56% |
| 2013 Q1 | 573.22 Million TWD | 6.26% |
| 2012 Q4 | 539.43 Million TWD | 0.97% |
| 2012 Q1 | 541.58 Million TWD | 1.39% |
| 2012 Q2 | 531.64 Million TWD | -1.83% |
| 2012 Q3 | 534.23 Million TWD | 0.49% |
| 2012 FY | 2.14 Billion TWD | -4.46% |
| 2011 FY | 2.24 Billion TWD | -25.32% |
| 2011 Q3 | 548.38 Million TWD | -0.31% |
| 2011 Q2 | 550.11 Million TWD | -10.47% |
| 2011 Q1 | 614.46 Million TWD | -23.56% |
| 2011 Q4 | 534.17 Million TWD | -2.59% |
| 2010 Q3 | 755.12 Million TWD | 2.31% |
| 2010 Q2 | 738.09 Million TWD | 3.67% |
| 2010 FY | 3 Billion TWD | 5.26% |
| 2010 Q1 | 711.97 Million TWD | 0.0% |
| 2010 Q4 | 803.89 Million TWD | 6.46% |
| 2009 FY | 2.85 Billion TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Grape King Bio Ltd | 10.63 Billion TWD | 87.767% |
| Standard Chem & Pharm CO., LTD. | 6.23 Billion TWD | 79.154% |
| ScinoPharm Taiwan, Ltd. | 3.18 Billion TWD | 59.175% |
| Lotus Pharmaceutical Co., Ltd. | 16.95 Billion TWD | 92.33% |
| LIWANLI Innovation Co., Ltd. | 38.88 Million TWD | -3244.874% |
| YungShin Global Holding Corporation | 7.02 Billion TWD | 81.492% |
| PhytoHealth Corporation | 162.48 Million TWD | -700.498% |
| SCI Pharmtech, Inc. | 1.2 Billion TWD | -8.019% |
| Formosa Laboratories, Inc. | 4.36 Billion TWD | 70.17% |
| PharmaEssentia Corporation | 5.1 Billion TWD | 74.524% |
| Bora Pharmaceuticals Co., LTD. | 14.2 Billion TWD | 90.84% |